FCCC LOGO Faculty Publications
Allen JE , Kline CL , Prabhu VV , Wagner J , Ishizawa J , Madhukar N , Lev A , Baumeister M , Zhou L , Lulla A , Stogniew M , Schalop L , Benes C , Kaufman HL , Pottorf RS , Nallaganchu BR , Olson GL , Al-Mulla F , Duvic M , Wu GS , Dicker DT , Talekar MK , Lim B , Elemento O , Oster W , Bertino J , Flaherty K , Wang ML , Borthakur G , Andreeff M , Stein M , El-Deiry WS
Discovery and clinical introduction of first-in-class imipridone ONC201
Oncotarget. 2016 Nov 08;7(45) :74380-92
PMID: 27602582    PMCID: PMC5342060    URL: https://www.ncbi.nlm.nih.gov/pubmed/27602582
Back to previous list
ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC201 has anti-proliferative and pro-apoptotic effects against a broad range of tumor cells but not normal cells. The mechanism of action of ONC201 involves engagement of PERK-independent activation of the integrated stress response, leading to tumor upregulation of DR5 and dual Akt/ERK inactivation, and consequent Foxo3a activation leading to upregulation of the death ligand TRAIL. ONC201 is orally active with infrequent dosing in animals models, causes sustained pharmacodynamic effects, and is not genotoxic. The first-in-human clinical trial of ONC201 in advanced aggressive refractory solid tumors confirmed that ONC201 is exceptionally well-tolerated and established the recommended phase II dose of 625 mg administered orally every three weeks defined by drug exposure comparable to efficacious levels in preclinical models. Clinical trials are evaluating the single agent efficacy of ONC201 in multiple solid tumors and hematological malignancies and exploring alternative dosing regimens. In addition, chemical analogs that have shown promise in other oncology indications are in pre-clinical development. In summary, the imipridone family that comprises ONC201 and its chemical analogs represent a new class of anti-cancer therapy with a unique mechanism of action being translated in ongoing clinical trials.
Allen, Joshua E Kline, C Leah B Prabhu, Varun V Wagner, Jessica Ishizawa, Jo Madhukar, Neel Lev, Avital Baumeister, Marie Zhou, Lanlan Lulla, Amriti Stogniew, Martin Schalop, Lee Benes, Cyril Kaufman, Howard L Pottorf, Richard S Nallaganchu, B Rao Olson, Gary L Al-Mulla, Fahd Duvic, Madeleine Wu, Gen Sheng Dicker, David T Talekar, Mala K Lim, Bora Elemento, Olivier Oster, Wolfgang Bertino, Joseph Flaherty, Keith Wang, Michael L Borthakur, Gautam Andreeff, Michael Stein, Mark El-Deiry, Wafik S ENG P30 CA016672/CA/NCI NIH HHS/ 2016/09/08 06:00 Oncotarget. 2016 Sep 1. doi: 10.18632/oncotarget.11814.